Relief of Hay Fever and Allergic Rhinitis Symptoms

This medication is commonly used to help with symptoms related to heightened physiological activity in the nose, throat, and eyes, which is characteristic of seasonal (hay fever) and perennial (year-round) allergies. The active ingredient is relevant for easing symptoms such as sneezing, a runny or itchy nose, an itchy throat, and the discomfort of itchy, watery eyes, which are commonly associated with allergic rhinitis. It is primarily used in conditions involving acute or disruptive episodes of these symptoms. It helps address symptom clusters that may become intense or disruptive during exposure to allergens. The use is relevant in situations where symptoms may intensify temporarily. This supportive relief helps improve day-to-day comfort during symptomatic periods and may assist with maintaining functional stability.

---

Management of Chronic Itching and Hives

The medication is applied across domains where additional symptomatic support is needed in situations where patients experience skin reactions. It is relevant for easing the symptoms of hives (urticaria) and other conditions where pronounced, persistent skin itching (pruritus) creates noticeable physiological strain. It is used for managing symptoms related to physical discomfort, such as bothersome skin itching, and may assist with easing the discomfort of associated redness and raised welts. This supportive relief may help patients cope more steadily with symptom fluctuations and is applied in scenarios where additional management of discomfort is required, especially for those experiencing recurrent manifestations of skin discomfort.

Quick Fact: Relief for Nasal, Ocular, and Skin Symptoms

Regulatory References

1. Cetirizine: MedlinePlus Drug Information

This information is strictly based on official government regulatory documents (e.g., EMA Summary of Product Characteristics, FDA Drug Facts Label). It defines the eligibility profile for Zodac (cetirizine hydrochloride).

Eligibility Category	Regulatory Status / Requirement
Absolute Non-Eligibility	Contraindicated in patients with known hypersensitivity to cetirizine, any formulation ingredients, or to its parent compound, hydroxyzine.
Age Limits (General Eligibility)	Typically eligible for adults and children 6 years and over. Children under 6 years of age must consult a doctor before use.
Organ Function Impairment	Restricted Use: Individuals with kidney disease or liver disease must ask a doctor before use, as dose reduction is required due to reduced drug clearance.
Geriatric Population	Restricted Use: Adults 65 years and over must ask a doctor before use.
Physiological Status	Pregnancy: Must ask a health professional before use. Breastfeeding: Use is not recommended.

The regulatory eligibility profile establishes clear boundaries for the drug's use. The absolute contraindication prevents use in populations with specific immunologic risks. Furthermore, conditional eligibility criteria mandate consultation and potential dose modification for patients with reduced organ clearance (kidney/liver impairment) and those in age extremes or specific physiological states (pregnancy/lactation).

Interactions with other medicines and products

Official regulatory documentation on Cetirizine Dihydrochloride (Зодак) establishes specific constraints regarding co-administration with certain medicinal products and substances, classified into pharmacokinetic and pharmacodynamic domains.

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Central Nervous System (CNS) Depressants.
Specific interacting medicines (if explicitly listed)	Ritonavir; Theophylline (400 mg/day).
Mechanistic basis of interactions (only if stated in label)	Alteration of pharmacokinetic clearance (decreased clearance); Pharmacodynamic reinforcement (additive CNS depression).

Official interaction statements:

• Ritonavir co-administration is documented to increase the extent of cetirizine exposure (AUC) by 42% and prolong its half-life, an outcome consistent with decreased clearance of cetirizine.
• Concurrent use with alcohol or other CNS Depressants may cause an additive reduction in alertness and further impairment of CNS performance. Caution is officially advised for these combinations.
• Co-administration with Theophylline (400 mg/day) is documented to result in a small decrease (approximately 16%) in cetirizine clearance.
• The presence of food is documented to decrease the rate of cetirizine absorption, delaying the time to peak concentration (T max), but does not alter the overall amount of exposure.

Regulatory information specifies that the increased exposure of cetirizine observed in the Ritonavir interaction remains within the range previously documented for subjects with mild renal impairment or the elderly population.

Зодак (Cetirizine) functions primarily as a potent antagonist of the peripheral H1 histamine receptor. This interaction involves competitive binding to the H1 receptor, which prevents the attachment of endogenous histamine, a key signaling molecule released from mast cells and basophils. By occupying the receptor site, the compound blocks the Gq/11 protein activation cascade typically initiated by histamine binding. This blockade consequently suppresses the intracellular signaling pathway involving phospholipase C, thereby regulating the subsequent increase in intracellular calcium and the generation of secondary messengers like IP3 and DAG.

Furthermore, the compound modulates the inflammatory response independent of H1 receptor antagonism. It demonstrates activity in inhibiting the migration and chemotaxis of inflammatory cells, including eosinophils and neutrophils, to targeted tissue sites. It also exerts an inhibitory effect on the release of various mediators, such as leukotrienes and certain cytokines, from mast cells and other immune cells. This dual mechanism—receptor blockade and inflammatory cell modulation—results in a systemic reduction of histamine-mediated physiological consequences.

How to Use Зодак (Cetirizine)

The administration of Зодак is governed by specific instructions focusing on the route, frequency, and dose adjustments necessary for different patient populations and clinical contexts. The medicine is primarily intended for oral administration, utilizing available forms such as film-coated tablets, syrup, and oral drops. For specialized acute care needs, an intravenous (IV) solution is also an approved route, administered as a push over one to two minutes.

Standard Labeled Regimens

The standard pattern for adults and adolescents (12 years and older) is a once-daily regimen of 10 mg. A starting dose of 5 mg once daily may be used for less severe symptoms. The maximum recommended dose for adults is 10 mg per 24 hours. Oral tablets may be taken with or without food, and should be swallowed with a glass of liquid, allowing for flexibility in the daily schedule.

Age Group	Standard Daily Dose	Frequency Pattern
Adults (12+ years)	10 mg (max)	Once Daily
Children (6–12 years)	10 mg	Once Daily or 5 mg Twice Daily
Children (2–5 years)	2.5 mg–5 mg	Once Daily or 2.5 mg Twice Daily

Population-Specific Adjustments

Usage requires modification for certain groups. For patients with renal impairment, a reduction in dose and frequency is necessary, such as 5 mg once daily or 5 mg every two days, depending on the degree of impairment. For children under 6 years of age, liquid formulations are mandated to ensure accurate dosing. In the event of a missed dose, the standard procedure is to take it as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Research evidence / Overview of studies for Зодак (Cetirizine)

---

Evidence for use in Seasonal Allergic Rhinitis (Hay Fever)

Research for this indication has primarily relied on Randomized Controlled Trials (RCTs). These trials were typically short-term, focusing on adults, adolescents, and children over 2 years old who were experiencing active symptoms during the allergy season. The main focus was to monitor patient-reported outcomes describing perceived discomfort, such as sneezing, itchy nose, and watery eyes, which were combined into symptom scores.

Studies described patterns observed in symptom measurements when comparing the groups receiving the substance to the placebo groups over short periods. This research provides context but not individual predictions; findings describe how patients reported their experience during episodes where symptoms become more noticeable.

---

Evidence for use in Chronic Urticaria (Hives)

Research also examined the substance in conditions involving persistent skin reactions, specifically Chronic Spontaneous Urticaria (CSU). The outcomes monitored were related to physical discomfort, such as the severity of itching (pruritus) and the size and number of visible wheals (hives). The research describes patterns observed in outcomes related to physical discomfort during the study period. Specific research also examined patterns in patient groups with refractory symptom profiles.

The available follow-up durations were limited, typically lasting up to three months. Therefore, long-term effects are not fully established, and the research provides limited insight into long-term management strategies.

---

Evidence for use in Perennial Allergic Rhinitis (Year-Round Allergies)

The substance was studied for Perennial Allergic Rhinitis. The research focused on outcomes related to continuous nasal and ocular symptoms, which were observed in populations of adults and children over 6 months. Research describes patterns of symptom severity measured during the study period as reported by the patient groups. This evidence contributes to the research base for conditions where symptoms may vary in intensity throughout the year.

---

Long-Term Studies and Follow-up Durations

The majority of high-quality research on this substance has focused on short-term outcomes and symptom management patterns for acute or episodic changes. The evidence base mainly contributes to understanding short-term changes and patterns of measured short-term symptom change.

There is a noticeable limited information for long-term outcomes regarding the use of the substance for continuous maintenance. Research has not thoroughly explored the patterns of continued use over many months or years, meaning the long-term effects are not fully established.

---

Evidence in Special Populations

Research has evaluated specific age groups, including pediatric patients (children) starting from 6 months of age for the studied oral formulations. Research describes the measured changes in symptoms for these specific age groups, but sample sizes were modest in the very youngest groups (under 2 years). Studies also monitored patterns in patient groups who have comorbidities. Data for certain vulnerable groups, such as pregnant or breastfeeding populations, remain insufficient.

Common questions about Зодак (FAQ)

Q: What is Зодак (Zodak) used for?

A: Зодак (Zodak), which contains the active substance cetirizine, is used to help relieve symptoms associated with seasonal and year-round allergies. This includes symptoms like sneezing, a runny or itchy nose, itchy or watery eyes, and an itchy throat.

It is also used to help relieve itching and redness associated with chronic urticaria (hives).

Q: Is Зодак (Zodak) a sedative or non-sedative antihistamine?

A: Зодак contains cetirizine, which is generally classified as a second-generation antihistamine. These are often referred to as 'non-drowsy' because they are less likely to cause significant drowsiness compared to older, first-generation antihistamines. However, some individuals may still experience drowsiness or mild sedation, particularly at higher doses. It is advised to observe your reaction to the medication before engaging in activities that require full mental alertness.

Q: Can Зодак (Zodak) be taken with other medications?

A: It is generally acceptable to take Зодак with most common pain relievers such as paracetamol or ibuprofen. However, it is essential to discuss all medications and supplements you are currently taking with a healthcare provider, especially if you are taking other medications that may cause drowsiness, as this could increase the risk of sedation.

Q: What are the common side effects of Зодак (Zodak)?

A: The most frequently reported side effects are generally mild and may include:

• Drowsiness or fatigue
• Headache
• Dry mouth
• Dizziness

If you experience any bothersome side effects, or if side effects appear severe or persistent, you should consult a healthcare professional.

Q: Does Зодак (Zodak) start working right away?

A: Clinical experience suggests that the relief of symptoms with Зодак (cetirizine) often begins relatively quickly, with some people reporting a noticeable effect within approximately one hour after taking the medication. A single dose is observed to provide relief that lasts for about 24 hours.

Q: Is it safe to take Зодак (Zodak) during pregnancy or while breastfeeding?

A: The use of any medication during pregnancy or breastfeeding should always be discussed with a healthcare professional.

• Pregnancy: Cetirizine should be used during pregnancy only if it is clearly necessary and only under the guidance of a doctor.
• Breastfeeding: Cetirizine is reported to be excreted in human breast milk. The use of this medication in nursing mothers is generally not recommended unless specifically advised by a doctor who has weighed the potential benefits and risks.

Storage Requirements

Зодак (cetirizine hydrochloride) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), according to regulatory labeling. The medicine should be kept in a cool, dry place, protected from excess moisture and heat; do not store the product in damp locations like a bathroom or above 25 C. To maintain stability, the tablets must remain in their original packaging (blister pack) until ready for use, and liquid forms should be kept tightly closed.

Child Protection and Disposal

A mandatory safety requirement is to keep the medicine out of the sight and reach of children at all times. Regarding disposal, unused or expired Зодак must not be thrown into household waste or flushed down the toilet. For proper environmental management, return the product to a pharmacist or doctor for disposal according to local pharmaceutical waste regulations.